The groundbreaking success of Sildenafil undeniably transformed the drug landscape, but investing in companies strongly reliant on unbranded versions presents a uncertain picture. Although early returns were substantial, the end of patents and the appearance of less expensive alternatives have weakened market share. Consequently, a thorough analysi